StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Candel Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$11.63M-43.3%
FY2023Dec 31, 2023$20.53M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$4.23M-70.0%
Q2 FY2025Jun 30, 2025$6.70M-59.4%
Q1 FY2025Mar 31, 2025$9.17M-51.6%
Q4 FY2024Dec 31, 2024$11.63M-43.3%
Q3 FY2024Sep 30, 2024$14.08M-31.1%
Q2 FY2024Jun 30, 2024$16.51M-18.9%
Q1 FY2024Mar 31, 2024$18.94M-6.6%
Q4 FY2023Dec 31, 2023$20.53M–
Q3 FY2023Sep 30, 2023$20.44M–
Q2 FY2023Jun 30, 2023$20.36M–
Q1 FY2023Mar 31, 2023$20.28M–

More Candel Therapeutics figures

See a number that looks wrong?